- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02752074
A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)
August 14, 2020 updated by: Incyte Corporation
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab (MK-3475) in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)
The purpose of the study is to assess the efficacy, safety, and tolerability when combining pembrolizumab with epacadostat or placebo in participants with unresectable or metastatic melanoma
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
706
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New South Wales
-
Camperdown, New South Wales, Australia
-
Westmead, New South Wales, Australia
-
Wollstonecraft, New South Wales, Australia
-
-
Queensland
-
Cairns, Queensland, Australia
-
Greenslopes, Queensland, Australia
-
-
South Australia
-
Kurralta Park, South Australia, Australia
-
-
Victoria
-
Melbourne, Victoria, Australia
-
-
-
-
-
Brussels, Belgium
-
Gent, Belgium
-
-
-
-
British Columbia
-
North Vancouver, British Columbia, Canada
-
-
Ontario
-
Ottawa, Ontario, Canada
-
Toronto, Ontario, Canada
-
-
Quebec
-
Montreal, Quebec, Canada
-
-
-
-
-
Santiago, Chile
-
Vina del Mar, Chile
-
-
-
-
-
Aarhus, Denmark
-
Herlev, Denmark
-
Odense C, Denmark
-
-
-
-
-
Bordeaux, France
-
Lille, France
-
Marseille, France
-
Paris, France
-
Pierre Benite, France
-
Reims, France
-
Rennes, France
-
Toulouse, France
-
Villejuif, France
-
-
-
-
-
Buxtehude, Germany
-
Essen, Germany
-
Hannover, Germany
-
Kiel, Germany
-
Tuebingen, Germany
-
-
-
-
-
Cork, Ireland
-
Dublin, Ireland
-
Galway, Ireland
-
-
-
-
-
Ramat Gan, Israel
-
-
-
-
-
Bergamo, Italy
-
Genova, Italy
-
Milano, Italy
-
Napoli, Italy
-
Padova, Italy
-
Siena, Italy
-
-
-
-
-
Asahikawa, Japan
-
Chuo, Japan
-
Fukuoka, Japan
-
Kagoshima, Japan
-
Kumamoto, Japan
-
Kurume, Japan
-
Kyoto, Japan
-
Matsumoto, Japan
-
Nagoya, Japan
-
Niigata, Japan
-
Okayama, Japan
-
Osaka, Japan
-
Sapporo, Japan
-
Sendai, Japan
-
Tokyo, Japan
-
Tsukuba, Japan
-
-
Sunto-gun
-
Susono, Sunto-gun, Japan
-
-
-
-
-
Seoul, Korea, Republic of
-
-
-
-
-
Chihuahua, Mexico
-
Distrito Federal, Mexico
-
Mexico City, Mexico
-
Monterrey, Mexico
-
-
-
-
-
Amsterdam, Netherlands
-
Nijmegen, Netherlands
-
-
-
-
-
Dunedin, New Zealand
-
Tauranga, New Zealand
-
-
-
-
-
Warszawa, Poland
-
-
-
-
-
Istra, Russian Federation
-
Moscow, Russian Federation
-
Saint Petersburg, Russian Federation
-
-
-
-
-
Kraaifontein, South Africa
-
-
Gauteng
-
Johannesburg, Gauteng, South Africa
-
Sandton, Gauteng, South Africa
-
-
Pretoria
-
Groenkloof, Pretoria, South Africa
-
-
Western Cape
-
Cape Town, Western Cape, South Africa
-
-
-
-
-
A Coruna, Spain
-
Barcelona, Spain
-
Madrid, Spain
-
Pamplona, Spain
-
San Sebastian, Spain
-
Sevilla, Spain
-
Valencia, Spain
-
-
Guipuzcoa
-
Donostia-San Sebastian, Guipuzcoa, Spain
-
-
-
-
-
Göteborg, Sweden
-
Lund, Sweden
-
Stockholm, Sweden
-
Uppsala, Sweden
-
-
-
-
-
Geneve, Switzerland
-
Lausanne, Switzerland
-
-
ZH
-
Zürich, ZH, Switzerland
-
-
-
-
-
Edinburgh, United Kingdom
-
London, United Kingdom
-
Manchester, United Kingdom
-
-
-
-
Alabama
-
Birmingham, Alabama, United States
-
-
Arizona
-
Scottsdale, Arizona, United States
-
-
Arkansas
-
Little Rock, Arkansas, United States
-
-
California
-
Los Angeles, California, United States
-
San Francisco, California, United States
-
Santa Barbara, California, United States
-
Santa Monica, California, United States
-
-
Colorado
-
Aurora, Colorado, United States
-
Denver, Colorado, United States
-
-
District of Columbia
-
Washington, District of Columbia, United States
-
-
Florida
-
Fort Lauderdale, Florida, United States
-
Jacksonville, Florida, United States
-
Ocala, Florida, United States
-
West Palm Beach, Florida, United States
-
-
Illinois
-
Chicago, Illinois, United States
-
Peoria, Illinois, United States
-
-
Iowa
-
Iowa City, Iowa, United States
-
-
Kansas
-
Kansas City, Kansas, United States
-
-
Maryland
-
Lutherville, Maryland, United States
-
-
Massachusetts
-
Boston, Massachusetts, United States
-
-
Michigan
-
Ann Arbor, Michigan, United States
-
-
Minnesota
-
Fridley, Minnesota, United States
-
-
Montana
-
Billings, Montana, United States
-
-
Nebraska
-
Omaha, Nebraska, United States
-
-
Nevada
-
Las Vegas, Nevada, United States
-
-
New York
-
Rochester, New York, United States
-
-
North Carolina
-
Charlotte, North Carolina, United States
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States
-
-
Tennessee
-
Nashville, Tennessee, United States
-
-
Texas
-
Austin, Texas, United States
-
Dallas, Texas, United States
-
-
Utah
-
Salt Lake City, Utah, United States
-
-
Virginia
-
Fairfax, Virginia, United States
-
-
Washington
-
Spokane, Washington, United States
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Have histologically or cytologically confirmed melanoma
- Have unresectable Stage III or Stage IV melanoma, as per AJCC staging system not amenable to local therapy
- A minimum of 1 measurable lesion by CT or MRI
- Provide a baseline tumor biopsy
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
Exclusion Criteria:
- Has received prior systemic treatment for unresectable or metastatic melanoma (except BRAF directed therapy)
- Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or IDO1 inhibitor or any other antibody or drug specifically targeting checkpoint pathways other than anti-CTLA-4 which is permitted in the adjuvant setting
- Has received prior adjuvant therapy, monoclonal antibody or an investigational agent or device within 4 weeks or 5 half-lives (whichever is longer)
- Has an active infection requiring systemic therapy
- Has known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
- Has known history of or is positive for Hepatitis B or Hepatitis C
- Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study treatment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Pembrolizumab + Epacadostat
|
|
ACTIVE_COMPARATOR: Pembrolizumab + Placebo
|
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free Survival
Time Frame: Assessed every 9 weeks for duration of study participation which is estimated to be 24 months
|
Progression-free survival, defined as the time from date of randomization until the earliest date of disease progression, as determined by independent central review of objective radiographic disease assessments per RECIST 1.1, or death from any cause, whichever comes first.
|
Assessed every 9 weeks for duration of study participation which is estimated to be 24 months
|
Overall Survival (OS) Rate at 6 Months
Time Frame: Assessed every 9 weeks of study participation which is estimated to be 24 months. The OS rate at Month 6 was calculated.
|
Defined as time from date of randomization to date of death due to any cause.
OS was calculated using product-limit (Kaplan-Meier) method for censored data.
|
Assessed every 9 weeks of study participation which is estimated to be 24 months. The OS rate at Month 6 was calculated.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (ORR)
Time Frame: Assessed every 9 weeks for duration of study participation which is estimated to be 24 months
|
Objective response rate (ORR) is defined as the percentage of the participants in the analysis population who have a confirmed complete response (CR) or partial response (PR) based on RECIST 1.1 by independent central review.
|
Assessed every 9 weeks for duration of study participation which is estimated to be 24 months
|
Safety and Tolerability, as Assessed by Percentage of Participants With Adverse Events
Time Frame: Through up to 90 days after end of treatment, up to 27 months
|
Safety and tolerability, as assessed by percentage of participants with adverse events and changes in laboratory parameters.
|
Through up to 90 days after end of treatment, up to 27 months
|
Duration of Response (DOR)
Time Frame: Assessed every 9 weeks for duration of study participation which is estimated to be 24 months
|
Defined as the time from the earliest date of qualifying response until earliest date of disease progression, per RECIST v1.1, or death from any cause, whichever comes first.
Includes participants with complete response or partial response.
|
Assessed every 9 weeks for duration of study participation which is estimated to be 24 months
|
Apparent Oral Clearance (CL/F) of Epacadostat
Time Frame: Through up to 30 days after the end of treatment, up to 25 months
|
Defined as oral dose clearance.
|
Through up to 30 days after the end of treatment, up to 25 months
|
Apparent Volume of Distribution (Vd/F) of Epacadostat
Time Frame: Through up to 30 days after the end of treatment, up to 25 months
|
Apparent volume of distribution after administration.
|
Through up to 30 days after the end of treatment, up to 25 months
|
Clearance (CL) of Pembrolizumab
Time Frame: Through up to 30 days after the end of treatment, up to 25 months
|
Through up to 30 days after the end of treatment, up to 25 months
|
|
Volume of Distribution (V) of Pembrolizumab
Time Frame: Through up to 30 days after the end of treatment, up to 25 months
|
Through up to 30 days after the end of treatment, up to 25 months
|
|
Formation of Anti-pembrolizumab Antibodies
Time Frame: Through up to 30 days after the end of treatment, up to 25 months
|
Evaluate the measurement of anti-drug antibodies (ADA).
|
Through up to 30 days after the end of treatment, up to 25 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
June 21, 2016
Primary Completion (ACTUAL)
January 8, 2018
Study Completion (ACTUAL)
August 16, 2019
Study Registration Dates
First Submitted
April 22, 2016
First Submitted That Met QC Criteria
April 22, 2016
First Posted (ESTIMATE)
April 26, 2016
Study Record Updates
Last Update Posted (ACTUAL)
August 27, 2020
Last Update Submitted That Met QC Criteria
August 14, 2020
Last Verified
July 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- INCB 24360-301 (ECHO-301)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Melanoma
-
H. Lee Moffitt Cancer Center and Research InstituteTurnstone Biologics, Corp.RecruitingMetastatic Melanoma | Conjunctival Melanoma | Ocular Melanoma | Unresectable Melanoma | Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma | Iris Melanoma | Acral Melanoma | Non-Cutaneous MelanomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Mucosal Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IA Melanoma | Stage IB Melanoma | Stage IIA MelanomaUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); University of VirginiaCompletedStage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage III Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin Melanoma | Stage 0 Skin Melanoma | Stage I Skin Melanoma | Stage II Skin MelanomaUnited States
-
MelanomaPRO, RussiaRecruitingMelanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma, Stage II | Melanoma, Uveal | Melanoma in Situ | Melanoma, OcularRussian Federation
-
National Cancer Institute (NCI)CompletedStage IV Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Iris Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIB Melanoma | Stage IIC MelanomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); National Comprehensive Cancer NetworkTerminatedRecurrent Melanoma | Stage IV Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIIA Intraocular Melanoma | Stage IIIB Intraocular Melanoma | Stage...United States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IIA MelanomaUnited States
-
Emory UniversityGenentech, Inc.Active, not recruitingStage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Unresectable Melanoma | Stage III Melanoma | Stage IIIA Skin Melanoma | Cutaneous Melanoma, Stage III | Cutaneous Melanoma, Stage IVUnited States
-
BiocadRecruitingMelanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma Metastatic | Melanoma Unresectable | Melanoma AdvancedIndia, Russian Federation, Belarus
Clinical Trials on pembrolizumab + epacadostat
-
Fox Chase Cancer CenterWithdrawnRecurrent/ Metastatic Endometrial CarcinomaUnited States
-
University of ChicagoWithdrawnHead and Neck CancerUnited States
-
University of ChicagoWithdrawnSquamous Cell Carcinoma of the Head and NeckUnited States
-
Incyte CorporationMerck Sharp & Dohme LLCCompletedLung CancerSpain, Ireland, Canada, Denmark, Japan, Israel, Korea, Republic of, Malaysia, United States, Turkey, Italy, Ukraine, Switzerland, Russian Federation, Poland, Australia, Estonia, United Kingdom
-
Incyte CorporationMerck Sharp & Dohme LLCCompletedUC (Urothelial Cancer)United States, France, Belgium, Israel, Spain, United Kingdom, Korea, Republic of, Taiwan, Australia, Netherlands, Japan, Germany, Ukraine, Canada, Ireland, Italy, Poland, Russian Federation
-
Incyte Biosciences International SàrlTerminatedMetastatic Cancer | Advanced MalignanciesUnited States
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...WithdrawnMuscle-invasive Bladder CancerItaly
-
University of ChicagoTerminatedHead and Neck Cancer | Head and Neck Squamous Cell CarcinomaUnited States
-
Incyte CorporationMerck Sharp & Dohme LLCCompletedUC (Urothelial Cancer)United States, Spain, Hungary, Israel, United Kingdom, Korea, Republic of, Taiwan, Denmark, France, Netherlands, Italy, Canada, Japan, Turkey, Germany, Ireland, Australia, Russian Federation
-
Georgetown UniversityMerck Sharp & Dohme LLC; Incyte CorporationUnknownThymic Carcinoma | Thymus Neoplasms | Thymus CancerUnited States